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Abstract
In the last decade, the role for noncoding RNAs in disease was clearly established, starting with microRNAs and
later expanded towards long noncoding RNAs. This was also the case for T cell acute lymphoblastic leukemia,
which is a malignant blood disorder arising from oncogenic events during normal T cell development in the
thymus. By studying the transcriptomic profile of protein-coding genes, several oncogenic events leading to T cell
acute lymphoblastic leukemia (T-ALL) could be identified. In recent years, it became apparent that several of these
oncogenes function via microRNAs and long noncoding RNAs. In this review, we give a detailed overview of the
studies that describe the noncoding RNAome in T-ALL oncogenesis and normal T cell development.
Keywords: T-ALL, Thymocytes, LncRNA, MicroRNA
Background
The noncoding RNAome
For decades, it was thought that only 2% of the human
genome was functional given its coding potential for
proteins. The remaining 98% of the genome was con-
sidered “junk DNA”. More recently, many studies have
indicated that a large portion (up to 75% or more) of
the human genome is actively transcribed while not
coding for proteins [1]. These so-called noncoding
RNAs consist of several distinct families including
microRNAs, small nuclear RNAs, PIWI-interacting
RNAs, and long noncoding RNAs. Interestingly, the
detection of noncoding RNAs led to a solution for the
G-value paradox that states that there is no correlation
between the amount of coding genes and the complex-
ity of the organism [2], while we do observe a correl-
ation between the complexity of the organism and the
ratio of the amount of noncoding genes to the total
genomic DNA. This finding, indirectly, suggests that
the increasing amount of noncoding RNA genes in the
genome of organisms can account for their complexity
[3]. In the last decade, the role of several of these non-
coding RNA families has been intensively studied and
key functions in both normal development and disease
were determined.
MicroRNAs
The Ambros team described the identification of the
first microRNA (miRNA) lin-4 in C. elegans in 1993 [4].
However, only from the beginning of this century, the
process of miRNA biogenesis was studied in depth
showing that miRNAs play an important role in develop-
ment and disease. MicroRNAs are short noncoding
RNAs of approximately 22 nucleotides that function as
post-transcriptional repressors of their target genes.
MiRNA biogenesis starts with transcription by RNA Pol
II of a primary miRNA (pri-miRNA), an RNA molecule
consisting of one to several hairpin structures [5, 6].
This pri-miRNA is subsequently cleaved to one hairpin
by the enzyme Drosha leading to the formation of a
precursor miRNA (pre-miRNA), which is then translo-
cated to the cytoplasm by Exportin-5 and processed by
the Dicer complex to a mature double stranded miRNA
[6–12]. In order to execute its gene regulatory function,
one strand is incorporated into the “RNA-induced si-
lencing complex” (RISC) thus guiding RISC to its target
messenger RNA (mRNA) through complementary base
pairing between the 3′ untranslated region (3′UTR) of
the target mRNA and the miRNA. In most cases, this
interaction will eventually lead to mRNA degradation
or inhibition of protein translation (for further details
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on miRNA biogenesis, we refer to a review by Ha and
Kim [13]). Remarkably, it has also been shown that the
miRNA interaction with mRNAs during cell cycle
arrest can recruit translation activators instead of trans-
lation repressors [14].
Typically, 3′UTRs of protein-coding genes harbor
multiple bona fide seed sequences for different miRNAs.
While the overall effect of a given miRNA on mRNA
expression or translation may be modest, the action of
multiple miRNAs on a single 3′UTR may significantly
alter the expression of the gene. At the same time, the
nature of this regulatory process creates the possibility
of time and context-specific gene regulation, which,
amongst others, is critical in normal development and
cellular functions. As such, it is not surprising that
microRNAs are implicated in various diseases, includ-
ing cancer [15–17]. Indeed, miRNAs can act as onco-
genes by repressing the expression of tumor
suppressors in the cell. The prototypical miRNA onco-
gene is the miR-17∼92 cluster (oncomiR-1) encompass-
ing six different miRNAs that are overexpressed in
several cancer entities [18]. This polycistron is directly
activated by the MYC transcription factor or repressed
by p53 [19–21] and controls a plethora of target genes
including PTEN, BIM, and p21 (CDKN1A), thereby
broadly impacting on the phenotype of cells [22, 23].
One of the first described tumor suppressor miRNAs is
encoded by the miR-15a/16-1 cluster, and this locus is
affected by recurrent 13q14 deletions in more than half
of chronic lymphocytic leukemia (CLL) cases with the
BCL2 oncogene as a primary target [24, 25]. Following
these landmark discoveries, many additional miRNAs
have been identified to act as oncomirs or tumor sup-
pressor miRNAs (reviewed in [16, 26, 27]). Recent stud-
ies also linked another class of small noncoding RNAs,
the PIWI-interacting RNAs (piRNAs) to cancer. PiR-
NAs were detected to be upregulated in several cancer
types, which could be linked to a poor prognosis. The
specific mechanism of action of piRNAs in cancer
biology should however be further investigated to find
out if and how they are driving cancer development
[28, 29].
Given the role for miRNAs in several cancer types and
promising preclinical studies, further initiatives towards
implementing miRNA-based therapies using miRNA
mimics or miRNA antisense inhibitors are taken (e.g.,
Mirna Therapeutics—www.mirnatherapeutics.com and
miRagen Therapeutics—www.miragentherapeutics.com).
Remaining challenges are the risk of a miRNA to act as
both an oncogene or tumor suppressor depending on
the cancer type, off-target effects, and the bioavailability
of miRNA mimics/inhibitors (reviewed in [30]). Further,
miRNAs or miRNA signatures can be used for prognos-
tic evaluation of cancer entities, as it was for example
detected that miRNA expression profiles of acute mye-
loid leukemia (AML) patients clustered the samples in
different groups that could be linked to cytogenetic risk
categories [31].
Long noncoding RNAs
While the existence of certain long noncoding RNAs
(lncRNAs) such as XIST (implicated in X-chromosome
inactivation) has been known for some time [32, 33], the
full recognition for lncRNAs as functionally relevant
RNA molecules has only emerged more recently. Gener-
ally speaking, lncRNAs, in contrast to miRNAs, repre-
sent a functionally very heterogeneous group of RNA
molecules that are defined by their length of at least 200
nucleotides and lack of protein-coding potential. While
many lncRNA genes share characteristics with protein-
coding genes in relation to splicing and polyadenylation,
many lncRNAs are expressed at low levels and show
poor species conservation compared to protein-coding
genes. These characteristics have caused skepticism on
the actual functional relevance of lncRNAs. On the other
hand, their complex secondary and tertiary structures
hint towards functional active molecules [34, 35], a no-
tion that is also further supported by their remarkable
tissue or cell type-specific expression pattern. Indeed, for
an increasing number of lncRNAs, the normal function
and its putative implication in certain diseases have been
reported but for the vast majority of lncRNAs such func-
tionalities remain to be discovered.
The total number of annotated lncRNAs is enormous
and may exceed 100,000 transcripts [36]. LncRNAs can
be classified according to their location and orientation
relative to protein-coding genes. LncRNAs overlapping
a protein-coding gene are categorized as “sense” or
“antisense” depending on their transcriptional orienta-
tion compared to the protein-coding gene. “Intronic”
lncRNAs are transcribed from an intron of another
transcript, whereas “intergenic” lncRNAs are located
between two coding genes without any overlap. A fifth
category is represented by those lncRNAs that are tran-
scribed on the opposite strand of a protein-coding gene,
with the transcription start sites located less than 1 kb
from each other. These lncRNAs are categorized as
“bidirectional.” (Reviewed in [37]).
At present, in-depth insights into the function of spe-
cific lncRNAs are rather limited. These studies how-
ever illustrate the broad possible cellular functions of
lncRNAs, with putative functions in transcription,
shaping genome architecture or epigenetic regulation.
Modulation (activation or repression) of transcription
by lncRNAs can be either through binding and regula-
tion of chromatin-modifying complexes (ex. PRC2 re-
cruitment [38, 39]) or transcription factors [40] or by
inhibition of the general transcription machinery [41, 42].
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Also, a specific class of lncRNAs transcribed at enhancers,
the so-called eRNAs, has been described [43, 44]. Post-
transcriptionally, lncRNAs have been detected to aid
mRNA processing and direct splicing [45, 46] and also
effects on translation or mRNA degradation have been
encountered 21307942. Some lncRNAs also have sev-
eral binding sites for a miRNA. These lncRNAs are
called competitive endogenous RNAs (ceRNAs) as they
titrate miRNAs away from their conventional target
mRNA [47–49] (Review on lncRNA functions in [50]).
As indicated above, long noncoding RNAs play a role
in normal cell development but also in several types of
heritable diseases and cancer [51]. One of the most well-
characterized and described lncRNAs in cancer is the
“metastasis-associated lung adenocarcinoma transcript
1” (MALAT1), a rather atypical lncRNA with a high
expression and species conservation. MALAT1 is
expressed in nuclear speckles and plays a role in nuclear
organization, transcription, and alternative splicing. It
has been shown that MALAT1 is upregulated in several
cancer types, enhancing cancer metastasis, and high
MALAT1 expression is correlated with poor prognosis
[52]. Another example of an oncogenic lncRNA involved
in several cancer types is “homeobox transcript antisense
RNA” (HOTAIR). It has been shown that HOTAIR func-
tions in the recruitment of the “polycomb repressive
complex 2” (PRC2) to specific loci in the genome, which
leads to H3K27 trimethylation and transcriptional silen-
cing of these loci [53].
In the last years, it was shown that a key subset of
lncRNAs is expressed from enhancer sites [54]. En-
hancers are loci on the genome that are bound by spe-
cific factors that modulate the transcriptional activity
of a nearby gene. These loci are demarcated in the gen-
ome by specific histone modifications (e.g., H3K27ac
and H3K4me1) and binding of key transcription factors
(e.g., p300 and the Mediator complex). The RNA mole-
cules expressed from these enhancers have been coined
enhancer RNAs (eRNAs) and are between 50 and 2000
nucleotides in length. It is hypothesized that several
eRNAs are necessary for the activity of enhancers, by
recruiting transcription factors to the enhancers and
aiding in the chromosomal looping to bring the enhan-
cer bound transcription factors to the gene promoter
[44, 55]. However, some concerns about the functional-
ity of these eRNA transcripts arose, as it appears that
only the act of transcription, but not the sequence, has
an influence on the function of the enhancer [56, 57].
T cell acute lymphoblastic leukemia
T cell acute lymphoblastic leukemia (T-ALL) is a
hematological malignancy caused by oncogenic trans-
formation of developing thymocytes. Normal T cell de-
velopment is a strictly regulated process that occurs in
the thymus. Immature thymocytes enter the thymus
from the bone marrow and migrate through several
thymic niches that drive specific stages of T cell develop-
ment [58–68]. During these stages, specific markers are
present at the membrane of these immature thymocytes
and genomic rearrangements attribute to the formation
of a functional T cell receptor, leading to a broad range of
different mature T cell types characterized by a specific T
cell receptor. During these stages of T cell development,
abnormal activation of oncogenes or inactivation of tumor
suppressor genes can lead to a differentiation arrest and
an uncontrolled expansion of immature thymocytes evolv-
ing to fully transformed T-ALL lymphoblasts [69].
Different genetic lesions have been identified as driv-
ing events, marking specific subgroups of T-ALL with
distinct gene expression patterns [70–74]: the TAL-
rearranged subgroup, the TLX1 subgroup, the TLX3
subgroup, and the HOXA-overexpressing subgroup.
Recently, a fifth subgroup with a poor prognosis, the
immature T-ALL subgroup, has been added with an
early T cell progenitor phenotype, but no single spe-
cific oncogenic driver event. This subgroup is marked
by the overexpression of multiple oncogenic factors as
MEF2C, LMO2, LYL1, and/or HHEX in several pa-
tients. To establish a full-blown leukemia, several
other oncogenic effects cooperate with these subtype-
specific driver events. For example, constitutive activa-
tion of the NOTCH1-signaling pathway is present in
over half of all T-ALL patients, regardless of the sub-
type, indicating that hyperactive NOTCH1 signaling
plays a central role in T-ALL biology [75]. The NOTCH-
signaling cascade is necessary in the early stages of T cell
development [58], but sustained NOTCH activation leads
to the malignant transformation of thymocytes. For more
in-depth information on T-ALL, we refer to several good
reviews [72, 76–78].
Noncoding RNAs have been extensively studied in
leukemia and normal hematopoiesis [79–85]; here, we
will focus on the role of miRNAs and lncRNAs in T-
ALL and T cell development.
Methodological approaches in miRNA and long
noncoding RNA research
MicroRNAs
Analytical platforms
MiRNA expression studies have initially used RT-qPCR
or microarray platforms, which enable simultaneous de-
tection of several hundreds of miRNAs. More recently,
advances in next-generation sequencing technology
made it also possible to determine the expression pro-
files of miRNAs by means of small RNA sequencing. A
major advantage of small RNA sequencing is that also
novel miRNAs and isomiRs (miRNAs with small varia-
tions compared to a reference miRNA sequence) get
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detected [86, 87]. The recently published miRQC study
gives a detailed overview of the strengths and weak-
nesses of the different miRNA detection methods and
platforms [88].
In silico target gene prediction
After the identification of miRNAs of interest, their po-
tential target mRNAs are usually identified based upon
the miRNA seed sequence, a seven-nucleotide sequence
mostly situated at positions 2–7 from the 5′-end that
can interact through complementary basepairing with
the 3′UTR of the miRNA. For this, several online tools
can be used, including miRDB (mirDB.org) [89], mi-
Randa (microRNA.org) [90], TargetScan (targetscan.org)
[91] and the recently developed miSTAR (mi-star.org)
[92]. These tools also enable the identification of all
miRNAs that potentially target an mRNA of interest.
The disadvantage of these in silico prediction algorithms
is that they focus on the interaction between the 5′
miRNA seed sequence and the 3′UTR of the miRNA,
but it has been shown that these interactions can also
take place in the 5′UTR or coding sequence of the
mRNA, that in only 60% of the cases the seed interac-
tions are perfectly complementary (others contain
bulged or mismatched nucleotides) and that sometimes
the 3′-end and not the 5′-end of the miRNA is used for
base pairing [93]. Furthermore, these methods do not take
into account the site accessibility as other RNA-binding
proteins might block the miRNA binding site [94].
Wet lab validation of miRNA target genes
Target prediction can also be achieved through several
in vitro methods. High-troughput sequencing methods
used for miRNA-mRNA interaction detection are for
example HITS-CLIP (high-throughput sequencing of
RNA isolated by crosslinking immunoprecipitation)
[95] or PAR-CLIP (photoactivatable ribonucleoside-
enhanced crosslinking and immunoprecipitation) [96],
which are methods developed to identify the specific
binding sites of RNA-binding proteins. In miRNA re-
search, these are specifically used to pull down the
RNA that interacts with proteins from the RISC-
complex, mostly AGO2. By comparing the pulled down
RNA after overexpression or knockdown of a miRNA
with a mock control, the exact interaction partners of a
miRNA can be identified [96–98]. Next to these
methods, all miRNA-mRNA interactions can be dir-
ectly mapped using the CLASH (crosslinking, ligation,
and sequencing of hybrids) technology [93]. In this
method, AGO-associated miRNA-target duplexes are
ligated, resulting in a chimeric RNA molecule that is
subsequently sequenced immediately revealing the
exact miRNA-mRNA interaction site [93]. While these
methods obtain valuable novel information on miRNA
targets, they are however labor intensive and technically
challenging. An overview of other in vitro methods can be
found in the review by Thomson et al. [94].
To validate potential miRNA-mRNA interactions, a lu-
ciferase reporter assay is the method of choice. In this
assay, the 3′UTR of the target mRNA is cloned next to a
reporter gene (e.g. luciferase) and a functional miRNA-
mRNA interaction should result in a decrease of the re-
porter gene signal after overexpression of the miRNA of
interest. A direct interaction between the miRNA and
the 3′UTR of the target gene could then be confirmed if
the decrease in signal is rescued by mutations of the
miRNA binding sites.
This reporter assay has also been applied in 3′UTR li-
brary screens in order to detect possible interactions of
known miRNAs with a certain gene of interest. In such 3′
UTR library screen, a plasmid containing the luciferase re-
port gene with the 3′UTR of the gene of interest and a
miRNA library are transfected together in HEK293T cells
[99]. Subsequent screening of the luciferase signal inten-
sity allows for the identification of potential functional
miRNA-mRNA interactions, which also need to be vali-
dated through subsequent mutagenesis assays.
In vivo studies of miRNA function in T-ALL development
NOTCH1-activating mutations are frequently detected
in human T-ALL and it has been shown that NOTCH1
serves as a potent oncogene that can drive T-ALL devel-
opment in mice. To study the role of miRNAs in T-ALL
in vivo, a NOTCH1-sensitized mouse model was used
[100]. To establish this model, fetal liver cells with
hematopoietic progenitor cells (HPCs) are isolated from
pregnant mice. These HPCs are then transduced with
ICN1 (active NOTCH1) and a vector containing an
antagomiR or premiR. After irradiation of the recipient
mice, these transduced HPCs are injected by tail vein in-
jection. The leukemia onset of these mice, compared
with control mice (ICN1 + a negative control miRNA),
gives an indication of the oncogenic or tumor suppres-
sive potential of the tested miRNA.
Junker et al. showed that the leukemia onset of this
mouse model is dependent on Dicer1-mediated biogen-
esis of miRNAs [101]. When HPCs with ICN1 overex-
pression were injected in conditional Dicer1 knockout
mice, where Dicer1 is inactivated when thymocytes or
leukemic cells transit from the double negative to double
positive (CD4+CD8+) stage, there was no leukemic onset
compared with control mice that all developed leukemia
in less than 100 days.
LncRNAs
Analytical platforms
In some early studies, lncRNAs have been investigated
using dedicated microarrays [102, 103]. More recently,
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RNA sequencing has become the method of choice, par-
ticularly given the significant tissue and spatial specific
expression of lncRNAs. RNA-sequencing detection of
lncRNAs requires a higher read depth in comparison to
protein-coding mRNAs, given the low expression levels
of most lncRNAs [104]. In addition to standard poly(A)
RNA sequencing, total RNA sequencing (with ribosomal
RNA depletion) is the preferred sequencing technique
for more exploratory studies, as it appears that several
lncRNAs do not have a poly(A) tail [105]. The major ad-
vantage of RNA sequencing is the ability to detect novel
lncRNAs or different splicing variants of a known
lncRNA [104, 106].
Guilt-by-association analysis
One of the major challenges in lncRNA research is the
selection of candidate lncRNAs for further functional
studies. Guilt-by-association analysis has been applied to
detect potential pathways in which a certain lncRNA of
interest is involved [107, 108]. This analysis is based on
the correlation of the candidate lncRNA expression pat-
tern in a sufficient large number of (patient) samples to
the expression of all protein-coding genes. Strong posi-
tive and/or negative correlations between the lncRNA
and several protein-coding genes could hint towards the
involvement of the lncRNA in the same pathways as
these protein-coding genes.
In vitro studies of lncRNAs
The cellular localization of the lncRNA can be deter-
mined by means of RNA-FISH (fluorescence in situ
hybridization) or cell fractionation. Nuclear lncRNAs are
probably involved in gene regulation or splicing control,
whereas cytoplasmic lncRNAs might have a plethora of
other functions such as miRNA sequestration, regulation
of translation, or protein complex formation. To detect
the interaction of the lncRNA with DNA, other RNAs,
or proteins, several techniques have been published.
These are based on the use of biotinylated oligonucleo-
tides complementary to the RNA of interest to pull
down its associated DNA, RNA, or proteins (ChIRP,
chromatin isolation by RNA purification [109]; CHART,
capture hybridization analysis of RNA targets [110];
RAP, RNA antisense purification [111]). On the other
hand, lncRNAs that are interacting with a protein of
interest can be detected by means of RIP (RNA immu-
noprecipitation) [112]. These technologies and many
more are nicely reviewed by Chu et al. [113]. Further-
more, the change in transcriptional profiles after
lncRNA knockdown could already hint towards potential
roles for the lncRNAs. However, it should be noted that
knockdown of lncRNAs is not always as straightforward
as for protein-coding genes. One major disadvantage is
the nuclear location of several lncRNAs, which makes
knockdown by siRNAs less efficient. The use of anti-
sense oligonucleotides (ASOs) could be a solution for
this problem as ASOs activate the RNaseH mechanism
in the nucleus to cut the RNA target. The use of the
cluster of regularly interspaced short palindromic re-
peats (CRISPR)/Cas9 technology to knockout lncRNAs
also imposes some obstacles, as lncRNAs might overlap
with protein-coding genes (sense or antisense) or with
regulatory elements (ex. enhancers). CRISPRi [91, 114],
using an inactivated Cas9 protein linked to a transcrip-
tion repressor, could be a possible solution to inhibit the
expression of the lncRNA. Here, the guide RNA is tar-
geted to the transcription start site of the lncRNA, inhi-
biting its expression.
In vivo studies of lncRNAs
The lack of sequence conservation of lncRNAs between
human and mice makes it very difficult to find ortholo-
gous lncRNAs for in vivo studies. However, for several
lncRNAs, the preservation of secondary structures, se-
quence domains, or interacting proteins could be de-
tected, as reviewed by Johnsson et al. [35]. One
remarkable feature detected by several groups is that the
promoter of lncRNAs showed a higher degree of se-
quence conservation than the exons [104, 107, 115, 116].
This topic is also reviewed by I. Ulitsky [117]. One way
to study the oncogenic potential of lncRNAs in vivo
without the knowledge of the mouse orthologous
lncRNA is the use of xenografts by implanting human
cell lines in mice. These cell lines could be modulated
by means of knockdown or overexpression of the
lncRNA and cancer progression could be monitored. In
T-ALL, a competition assay could be used where wild
type and modulated cell lines with specific fluorescent
markers are mixed and consequently injected in mice.
After a few weeks, the fluorescent signal ratios can then
be measured by flow cytometric analysis of the blast
cells [118].
Oncomirs and tumor suppressor miRNAs in T-ALL
T-ALL miRNA oncogenes
MiR-19b was one of the first oncogenic miRNAs de-
scribed in T-ALL by the Wendel team [119]. This
miRNA is part of the abovementioned mir-17~92 clus-
ter. The oncogenic role of the cluster in T-ALL was
strongly suggested through the finding of a new trans-
location t(13;14)(q32;q11) that juxtaposed the miR-
17~92 cluster to the TCRA/D locus thereby placing it
under the immediate control of the strong TCRA/D en-
hancer. This translocation occurred together with a
t(9;14)(q34;q11) translocation that contributes to the ab-
errant activation of the NOTCH1 gene. The coexistence
of these two translocations hinted towards the collabor-
ation of NOTCH1 and the miR-17~92 cluster in T-ALL
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development. In order to define which members of the
cluster effectively contributed to T-ALL formation,
cytokine-dependent FL5-12 lymphocytes were trans-
duced with individual miRNAs of the cluster followed by
IL-3 withdrawal. In these assays, miR-19b showed the
strongest oncogenic capacity, which is in line with the
fact that miR-19b shows the highest expression of all
members of the miR-17~92 cluster in human T-ALL. A
NOTCH1-sensitized mouse model was subsequently
used to confirm the oncogenic role of miR-19b in vivo.
Finally, target prediction algorithms in combination with
functional validation experiments identified different
components of the PI(3)K signaling pathway as direct
miR-19b targets, including PP2A, PRKAA1, BIM, and
PTEN.
A few years later, Ye et al. performed a large bio-
informatics screening to point out central hubs in the T-
ALL network [120]. To this end, combinations of genes
and miRNAs known to be involved in T-ALL were
tested with target prediction algorithms. Furthermore,
possible transcription factor regulatory relationships
(feed forward and feedback loops) were determined
based on predicted transcription factor binding sites
near T-ALL genes and miRNAs. This led to a complex
network that contained 21 T-ALL genes, 21 T-ALL miR-
NAs, and 28 transcription factors. The main hubs in this
in silico established network contained 4 miRNAs of the
miR-17~92 cluster, again revealing an important role for
this cluster in T-ALL. In addition, these authors revealed
that miR-19 could regulate NF-κB signaling through dir-
ect targeting of CYLD.
In 2011, a more in-depth study was performed towards
identifying oncogenic miRNAs targeting known tumor
suppressor genes in T-ALL [121]. In this study, miRNA
expression data was compared with an unbiased miRNA
library screen, computational target prediction analyses
and in vivo modeling to identify the most promising
candidates. Eventually, this resulted in the identification
of a network of five oncogenic miRNAs (miR-19b, miR-
20a, miR-26a, miR-92, and miR-223), which shared a
panel of direct tumor suppressor target genes previously
implicated in T-ALL biology (IKZF1, PTEN, BIM, PHF6,
NF1, and FBXW7). MiRNAs with the same target genes
also showed a cooperative effect on cell viability. Three
of these miRNAs (miR-19b, miR-20a, and miR-92) be-
long to the oncogenic miR-17~92 cluster, whereas
miR-223 was subsequently shown to be activated by
TAL1 [122, 123] and NOTCH1 [124], two important
T-ALL oncogenes (discussed below), further support-
ing the original observations of this study.
In subsequent studies, additional miRNAs with an
oncogenic role in the development of T-ALL have been
reported. MiR-128-3p is highly expressed in T-ALL pa-
tients and has increased expression in T-ALL samples
compared to healthy donor thymocytes. MiR-128-3p dir-
ectly inhibits the expression of the tumor suppressor
PHF6 and overexpression caused accelerated leukemia
onset in the NOTCH1-sensitized mouse model [99].
MiR-21 is highly expressed in both murine and human
T-ALL and is involved in the inhibition of apoptosis,
probably by regulating Pdcd4, known to play a role in
the apoptosis pathway by inhibition of BCL-xL transla-
tion [101]. Another example is miR-142-3p, which is
upregulated in T-ALL patient samples compared to thy-
mocytes of healthy donors and is one of the top
expressed miRNAs in T-ALL [121, 125]. MiR-142-3p
plays a role in cell proliferation through an indirect in-
hibition of cAMP (cyclic AMP) and PKA (protein kinase
A), an inhibitor of T cell leukemia proliferation. Further-
more, miR-142-3p directly targets glucocorticoid recep-
tor alpha (GRα), with high miR-142-3p levels being
involved in glucocorticoid resistance, and is linked to
poor prognosis [125]. MiR-149* was detected as being
upregulated in T-ALL cell lines and bone marrow of T-
ALL patients in comparison to peripheral blood. This
miRNA promotes cell proliferation and reduces cell
apoptosis and might perform this oncogenic function by
its direct targeting of JunB [126].
Finally, other studies made use of correlation ana-
lyses between miRNA and mRNA expression in T-ALL
patient samples to detect potential novel oncomiRs.
For example, the expression of miR-590 is negatively
correlated with RB1 expression and it was found that
miR-590 plays an oncogenic role in cell proliferation
and migration and invasion, by directly targeting RB1
[127]. A second example is the negative correlation
between miR-181a and EGR1, a tumor suppressor in
several other cancer entities. The miR-181a/EGR1 pair
probably has a role in cell cycle regulation [128]. miR-
181a is also linked to the NOTCH1 signaling pathway
which is discussed further in more detail [129].
T-ALL tumor suppressor miRNAs
The Wendel team also conducted a screening for miRNAs
with a tumor suppressor function [130]. They selected
abundantly expressed miRNAs in thymocytes from
healthy donors that had at least a 10-fold lower expres-
sion in primary T-ALL samples. Further selection was
performed by in vitro proliferation assays after overex-
pression of the miRNAs. This approach eventually led
to the identification of five miRNAs (miR-29, miR-31,
miR-150, miR-155, and miR-200) with tumor suppres-
sive effects in vitro and in vivo. To identify the poten-
tial mRNA targets by which these miRNAs performed
their tumor suppressive effect, predicted targets with
higher expression in T-ALL patients as compared to
healthy donors were selected, in keeping with a poten-
tial oncogenic function of the targets. The known T-
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ALL oncogene MYB (for miR-150, miR-155, and miR-
200) and also a potential new oncogene in T-ALL,
HBP1 (for miR-29, miR-31, miR-155, and miR-200) ap-
peared to be key targets of this tumor suppressive
miRNA network. Remarkably, it was also shown that
the oncogenic NOTCH1/c-MYC pathway inhibited the
expression of miR-31, miR-150, and miR-155.
To further evaluate the post-transcriptional regulation
of the T-ALL oncogene MYB by miRNAs, the Speleman
team performed a miRNA library screen testing the pu-
tative interaction of 470 miRNAs with the 3′UTR of
MYB by a luciferase reporter assay. Combined with
mRNA and miRNA expression profiling data from 64 T-
ALL patient samples, miR-193b-3p was detected as a
direct negative regulator of MYB. MiR-193b-3p was also
lower expressed in TAL-rearranged T-ALL patients, in
keeping with MYB upregulation in this T-ALL genetic
subtype. Importantly, inhibition of miR-193b-3p in the
NOTCH1-sensitized mouse model significantly increased
leukemia onset [131].
In another study, miR-204 was detected as a potential
tumor suppressive miRNA as it was lower expressed in
T-ALL patient samples compared to normal T cells from
peripheral blood. This was further supported by the ob-
servation that miR-204 could inhibit proliferation, mi-
gration, and invasion of T-ALL cell lines and directly
targets SOX4, a protein involved in tumorigenesis of
AML [132].
T-ALL subtype-specific miRNAs
As indicated above, T-ALL samples can be classified in
different genetic subtypes, which display unique gene ex-
pression signatures [70–74]. Although different studies
have linked miRNAs to specific genetic subtypes of hu-
man T-ALL, a comprehensive study on the expression of
subtype-specific miRNAs in human T-ALL remains to
be accomplished.
One of the first papers that described miRNAs in T-
ALL linked high expression of the miR-17~92 cluster to
TLX1, TLX3, and NKX2-5 overexpressing T-ALL pri-
mary samples and cell lines. This miRNA cluster seems
to be activated by these transcription factors and im-
poses increased cell survival through the inhibition of
E2F1 [133].
Schotte et al. linked miR-196b to the HOXA-
overexpressing subtype with MLL-rearrangements,
CALM-AF10, or SET-NUP214 fusions or inversion on
chromosome 7 [134]. Since miR-196b is located in the
HOXA-locus, this link might be due to co-activation.
High expression of miR-196a and miR-196b was subse-
quently also linked to T-ALL samples with an early
immunophenotype and concomitant expression of
CD34 and CD33 [135].
Furthermore, miR-223 has been linked to a myeloid-
like T-ALL phenotype [136] but has also been identified
as a target of the TAL1 transcription factor oncogene
[122, 123]. Moreover, high expression of miR-221 and
miR-222 has been linked to the poor prognostic subtype
of human early T cell precursor acute lymphoblastic
leukemia (ETP-ALL), and it was discovered that miR-
222 directly inhibits the expression of the proto-
oncogene ETS1 [137]. In the same study, miR-19a and
miR-363 were detected as specifically downregulated in
ETP-ALL.
MiRNAs in the NOTCH1 regulatory network
As mentioned in the introduction, NOTCH1-activating
mutations are present in over half of all T-ALL patients.
A plethora of canonical NOTCH1 downstream protein-
coding targets have been described over the last decade.
More recently, it became apparent that also miRNAs
play a role in the NOTCH1 regulatory network in the
context of T-ALL development.
Li et al. described miR-451 and miR-709 as possible
tumor suppressor miRNAs in murine T-ALL. These
miRNAs are downregulated in T-ALL and show a dy-
namic expression pattern during normal T cell develop-
ment. The tumor suppressor role of these miRNAs was
further established by a delayed leukemia onset after
overexpression of miR-451 or miR-709 in the NOTCH1-
sensitized mouse model. MiR-451 and miR-709 directly
target c-Myc, a known oncogene activated by NOTCH1
in T-ALL. Next to c-MYC, miR-709 also directly targets
Ras-GRF1 and Akt. Motif analysis followed by ChIP-
sequencing revealed the positive regulation of these
miRNAs by E2A, which itself is inhibited by NOTCH1
signaling. The NOTCH1/miR-451/c-MYC axis also
plays a role in human T-ALL (miR-709 has no human
homologue) [138].
Later, this network was further expanded by adding
a feed forward loop between NOTCH1 and c-MYC
that was regulated by the tumor suppressive miRNA,
miR-30a [139]. The expression of miR-30a is lower in
T-ALL patient samples with hyperactive NOTCH1
compared to NOTCH1 wild-type cases. NOTCH1 sig-
naling activates the expression of c-MYC and c-MYC
inhibits miR-30a expression [140]. Target prediction
analysis and reporter assays then demonstrated that
miR-30a targets NOTCH1. This implies that oncogenic
activation of NOTCH1 leads to an overexpression of c-
MYC, followed by a miR-30a downregulation. This then
releases the inhibition of NOTCH1 expression by miR-30a
[139].
It has also been shown that NOTCH1-induced murine
T-ALL development was hampered by the deletion of
the miR-181a-1/b-1 gene. Remarkably, the effects of
miR-181a-1/b-1 change depending on the expression
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level of Notch1. If the expression of Notch1 is high, the
deletion of the miR-181a-1/b-1 gene strongly delays T-
ALL development, whereas the deletion leads to a full
inhibition of T-ALL if Notch1 expression is lower.
miR-181a regulates Notch signaling by inhibition of
Nrarp, which is a negative regulator of the NOTCH1
downstream signaling. Furthermore, miR-181a was
also necessary in early T cell development, where it in-
hibits negative regulators of pre-T cell receptor signal-
ing (ex. Dusp5 and Dusp6) [129].
MiR-223 was detected as differentially expressed in
murine Notch-modulated T-ALL models. Motif analysis
and ChIP-sequencing showed the binding of the ICN1
complex and NF-κB to the promoter of miR-223, which
leads to the activation of transcription of this miRNA.
MiR-223 itself further negatively regulates FBXW7, a
known tumor suppressor gene in T-ALL. In contrast to
this finding, γ-secretase inhibitor (GSI) treatment (which
inhibits downstream NOTCH1 signaling) showed upreg-
ulation of miR-223 in GSI-resistant T-ALL cell lines
[124]. These contradictory results could later be ex-
plained by the activation of C/EBPα after GSI treatment,
which can activate miR-223 as well [141]. MiR-223 is
also important in the TAL1 downstream pathway, which
will be discussed in the next paragraph.
MiRNAs up- and downstream of the TAL1 oncogene
TAL1/SCL overexpression is one of the major oncogenic
events in T-ALL, which could delineate a specific T-ALL
subtype. Mansour et al. studied the downstream miR-
NAs of TAL1 [122]. In this study, miR-223 was the most
promising candidate as it was most strongly differentially
expressed upon TAL1-knockdown and direct binding of
TAL1 to the miR-223 promoter was shown. Next to that,
TAL1-positive T-ALL cells needed miR-223 for their sus-
tained cell survival. They also showed that the expres-
sion of TAL1 and miR-223 is strongly correlated during
normal T cell development, implicating that the expres-
sion of miR-223 is high in early T cell progenitors and
low from the DN3a stage onto more mature T cell
stages. Furthermore, it was proven that miR-223 directly
inhibits the expression of FBXW7 and in this way sup-
ports the oncogenic function of TAL1 [121, 122]. By
means of TAL1-overexpression, Correia et al. also
showed the direct activation of miR-223 but also direct
repression of miR-146b-5p by TAL1. Direct or indirect
TAL1-regulated miRNAs were predicted (by in silico
analysis) to target several genes in the TAL1 downstream
pathways [123].
Because several T-ALL patients show TAL1 overrex-
pression without a known cause, Correia and colleagues
hypothesized that the downregulation of miRNAs that
target TAL1 might be a novel oncogenic event in T-ALL.
Target prediction algorithms revealed several miRNAs
with potential binding sites in the 3′UTR of TAL1. Five
of these miRNAs (miR-101, miR-520d-5p, miR-140-5p,
miR-448, and miR-485-5p) could be validated as direct
inhibitors of TAL1, of which four miRNAs (not miR-
520d-5p) where lower expressed in T-ALL patient sam-
ples compared to normal bone marrow cells [142].
An overview of the described miRNA-mRNA inter-
action can be found in Fig. 1 and in Table 1.
Long noncoding RNAS implicated in T-ALL
In contrast to miRNAs, lncRNAs emerged more recently
on the cancer scene and fewer publications have been
published so far. The possible functions of lncRNAs are
most probably very diverse as exemplified by those de-
scribed so far in the lncRNA field. Moreover, modulating
lncRNAs and identifying their function can be notoriously
difficult and require extensive investigations.
NOTCH1-driven lncRNAs
The first comprehensive study of lncRNAs in T-ALL
comprised mRNA and lncRNA expression profiles of
T-ALL cell lines and primary T-ALL patient samples by
means of deep total RNA sequencing. Direct NOTCH1-
regulated lncRNAs were determined by pharmacological
inhibition of the NOTCH1 pathway by means of GSIs
in two T-ALL cell lines and by NOTCH/RBPJκ ChIP-
sequencing. Trimarchi et al. prioritized LUNAR1
(leukemia-induced noncoding activator RNA 1) as a
NOTCH1-induced candidate oncogenic lncRNA for
further functional analysis. This was based on its strong
correlated expression with IGF1R, as IGF1R was already
previously linked to T-ALL development. In addition,
the LUNAR1 locus is characterized by an active pro-
moter based on the chromatin structure as determined
in cell lines with hyperactive NOTCH1 signaling and
the transcript structure of LUNAR1, as determined by
“rapid amplification of cDNA ends” (RACE), has no
protein-coding potential. Hi-C and 3C (chromosome
conformation capture) proved a physical interaction be-
tween the LUNAR1 promoter and an active enhancer in
the last intron of its neighboring gene IGF1R. Also,
knockdown of LUNAR1 led to a decrease in expression
of IGF1R, whereas overexpression of LUNAR1 did not
have any effect on IGF1R, in keeping with a cis-acting
role of LUNAR1. Next, in-depth in vitro and in vivo ex-
periments could unravel the mechanism by which
LUNAR1 has an oncogenic role in T-ALL. Xenograft
assays with a mix of human T-ALL cells with or with-
out knockdown of LUNAR1 revealed tumors with a sig-
nificant loss of representation of cells where LUNAR1
was depleted, again proving an oncogenic role of
LUNAR1 in T-ALL development. On a molecular level,
Trimarchi and colleagues could show that LUNAR1 is
involved in the recruitment of the Mediator complex
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and RNA Pol II to the enhancer located in the last in-
tron of IGF1R, leading to full transcriptional activation
of the IGF1R gene [118].
In a parallel study, the repertoire of NOTCH1-driven
lncRNAs in T-ALL was further unraveled by Durinck et
al., through characterization of lncRNAs of which the
expression was affected by GSI treatment of T-ALL cell
lines and under control of NOTCH signaling in CD34+
thymocytes [61, 102]. By means of RNA - sequencing, a
set of known and novel lncRNAs that are directly regu-
lated by NOTCH1 in both normal and malignant T cell
development was identified, with one of the most prom-
inent NOTCH1 candidate lncRNAs apparent from both
in vitro model systems being the previously described
LUNAR1. Integration of the obtained RNA-seq profiles
of GSI-treated cell lines and NOTCH1-stimulated CD34+
T cell progenitors with NOTCH1 ChIP-sequencing pro-
files showed that the majority of the identified NOTCH1-
regulated lncRNAs showed ICN1 binding in the vicinity
of their promoter. In addition, a subset of those was also
bound by MED1 and BRD3, hinting towards a potential
role of enhancer RNAs for a subset of the identified
NOTCH1-regulated lncRNAs [102].
In addition to the above studies focusing on NOTCH1-
controlled lncRNAs, yet another investigation identi-
fied NALT (Notch1-associated lncRNA in T-ALL) as a
lncRNA involved in the regulation of NOTCH1 ex-
pression. It is located 400 bp upstream of the
NOTCH1 locus in the antisense direction and is
higher expressed in T-ALL patient bone marrow com-
pared to healthy control samples. In vitro and in vivo
knockdown experiments could further show a poten-
tial role for NALT as a transcriptional activator in-
volved in cell proliferation [143].
T-ALL subtype-specific lncRNAs
As indicated above, gene expression studies have been
shown to allow genetic subgroup classification. To ex-
plore this for lncRNA expression profiles, the Speleman
team screened a cohort of 64 primary T-ALL patient
samples for expression of all protein-coding genes and
13,000 lncRNAs [144]. This cohort consisted of 15 im-
mature, 17 TLX1/3, 25 TAL-rearranged, and 7 HOXA-
overexpressing T-ALL cases. This study allowed defining
subsets of lncRNAs specific for each of the T-ALL gen-
etic subtypes. Furthermore, the authors linked the
Fig. 1 Overview of the noncoding RNAs implicated in T-ALL. miRNAs (blue text) and lncRNAs (green text) studied in T-ALL oncogenesis. The
mRNAs linked to the ncRNAs are annotated in the filled circles. Bona fide oncogenes and tumor suppressor genes in T-ALL are annotated in respectively
red and blue background. Dashed lines represent indirect interactions. miRNAs of the miR-17~92 cluster are highlighted with a red circle
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Table 1 miRNAs implicated in T-ALL biology
miRBase release 21 Function Direct targets Refs
miR-19a hsa-miR-19a-3p ONC CYLD [120, 137]
ETP low
miR-19b hsa-miR-19b-3p ONC BIM, CYLD, PP2A, PRKAA1, PTEN [119–121]
miR-20a hsa-miR-20a-5p ONC BIM, PHF6, PTEN [121]
miR-21 hsa-miR-21-5p ONC PDCD4 [101]
miR-26a hsa-miR-26a-5p ONC BIM, PHF6, PTEN [121]
miR-29 hsa-miR-29a-3p TSG HBP1 [129]
miR-30a hsa-miR-30a-5p/3p MYC repressed NOTCH1 [139, 140]
Targets NOTCH1
miR-31 hsa-miR-31-5p TSG HBP1 [130]
miR-92 hsa-miR-92a-3p ONC BIM, FBXW7, IKZF1, NF1, PTEN [121]
miR-101 hsa-miR-101-3p Targets TAL1 TAL1 [142]
miR-128-3p hsa-miR-128-3p ONC PHF6 [99]
miR-140-5p hsa-miR-140-5p Targets TAL1 TAL1 [142]
miR-142-3p hsa-miR-142-3p ONC cAMP, GRα, PKA [125]
miR-146b-5p hsa-miR-146b-5p TAL1 repressed – [123]
miR-149* hsa-miR-149-3p ONC JunB [126]
miR-150 hsa-miR-150-5p TSG MYB [130]
miR-155 hsa-miR-155-5p TSG HBP1, MYB [130]
miR-181a hsa-miR-181a-5p ONC EGR1, NRARP [128]
miR-193b-3p hsa-miR-193b-3p TSG MYB [131]
TAL-R low
miR-196a hsa-miR-196a-5p IMM high ERG [135]
miR-196b hsa-miR-196b-5p HOXA high ERG [134, 135]
IMM high
miR-200c hsa-miR-200c-3p TSG HBP1, MYB [130]
miR-204 hsa-miR-204-5p TSG SOX4 [132]
miR-221 hsa-miR-221-3p ETP high – [137]
miR-222 hsa-miR-222-3p ETP high ETS1 [137]
miR-223 hsa-miR-223-3p ONC FBXW7 [121–124, 136]
Myeloid high
TAL-R high
NOTCH1 activated
TAL1 activated
miR-363 hsa-miR-363-3p ETP low – [137]
miR-448 hsa-miR-448 Targets TAL1 TAL1 [142]
miR-451 hsa-miR-451a NOTCH1 repressed c-MYC [138]
miR-485-5p hsa-miR-485-5p Targets TAL1 TAL1 [142]
miR-520d-5p hsa-miR-520d-5p Targets TAL1 TAL1 [142]
miR-590 hsa-miR-590-5p ONC RB1 [127]
miR-92 hsa-miR-92a-3p ONC BIM, FBXW7, IKZF1, NF1, PTEN [121]
The most recent miRBase annotation was retrieved using the miRBase Tracker, www.mirbasetracker.org [160]
ONC oncogenic miRNA, TSG tumor suppressor miRNA, ETP ETP-ALL, TAL-R TAL-rearranged T-ALL, IMM immature T-ALL, HOXA HOXA-overexpressing T-ALL
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lncRNA expression pattern in these T-ALL subtypes to
the different stages of healthy T cell development in the
thymus. As the immature T-ALL subtype lymphoblasts
occur from a differentiation arrest early during T cell de-
velopment (CD34+ thymocytes), it appeared that several
lncRNAs that are upregulated in the immature T-ALL
subtype are also higher expressed in the CD34+ thymo-
cytes compared to later stages during T cell develop-
ment. These lncRNAs might be involved in normal T
cell development. On the other hand, lncRNAs were
identified in the immature T-ALL subtype group with
significantly higher expression in immature T-ALL as
compared to CD34+ thymocytes, revealing a potential
oncogenic role during T-ALL development. The same
comparisons could be made for the TAL-rearranged pa-
tients that resemble a later differentiation arrest during
T cell development, the double positive CD4+CD8+ stage
[103].
Noncoding RNAs in T cell development
Normal thymopoiesis is a tightly regulated developmen-
tal process that is initiated with CD34+ early T cell pro-
genitors that migrate from the bone marrow towards the
thymus. Within this thymic microenvironment, discrete
developmental stages of T cell development can be iden-
tified through a combination of cell surface markers
(CD34, CD4, CD8, CD3, etc.) and each of these stages
contains a distinct transcriptional profile [58–68] (Fig. 2).
As noncoding RNAs show a very tissue and cell type-
specific expression pattern, the possible involvement of
miRNAs and lncRNAs in the clearly distinct steps of T
cell development is quite obvious.
MicroRNAs in T cell development
Several miRNAs have been discovered over the last years
that are involved in normal T cell development in the
thymus. Their overall relevance was nicely illustrated by
a study by Cobb et al. that showed that deletion of Dicer
in early T cell progenitors in mice led to a decrease in
thymic cellularity as a consequence of reduced survival
of the αβ T cell lineage, thus revealing a role for miR-
NAs in the double negative to double positive stage
transition [145, 146]. In addition, miRNA processing by
Dicer is also necessary for the positive selection of thy-
mocytes and the transition from the double positive to
the CD8+-single positive stage, as shown in conditional
Dicer knockout mice with a CD4-Cre transgene [147]. It
has also been shown that miRNAs and even isomiRs
change in expression during T cell development, indicat-
ing that not only the expression but also the processing
of the miRNAs is altered during thymopoiesis [148].
Despite their clear importance, data on the role of in-
dividual miRNAs is rare. MiR-181a, however, not only
plays a role in NOTCH1-driven T-ALL but also appears
Fig. 2 MicroRNAs involved in T cell development in the thymus. Immature T cells migrate from the bone marrow to the thymus where they go
through several stages of differentiation (early T cell prognitors (ETP), double negative T cells (DN), double positive T cells (DP) and single positive
T cells (SP)), which are marked by different membrane receptors (CD34, CD1a, CD4, CD8, TCR, etc). Mature T cells leave the thymus as either CD4+ or
CD8+ αβ T cells or γδ T cells and perform several functions in the immune defense of the body. MicroRNAs play a role during this process, with
proven function for the miR-17~92 cluster and miR-181a
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to be involved during normal T cell development. The
expression of miR-181a is high at the double positive T
cell stage and decreases during development, with al-
most no expression in differentiated T cells [149, 150].
Furthermore, it has been shown that miR-181a increases
thymocyte sensitivity by directly inhibiting the expres-
sion of DUSP5, DUSP6, SHP2, and PTPN22 which are
negative regulators of TCR signaling [151]. miR-181a
also appears to be involved in the regulation of positive
and negative selection of thymocytes [150, 151] (Fig. 2).
The miR-17~92 cluster inhibits the expression of
PTEN and of the pro-apoptotic protein BIM, which leads
to T cell survival at the DN2 stage of T cell development
[152]. It has also been shown that the miR-17~92 cluster
is necessary for cell survival at the double negative to
double positive transition of T cell development by regu-
lating the IL7R receptor surface expression and the re-
sponse to IL-7 [153]. Furthermore, this cluster is also
involved in positive and negative selection of thymocytes
[152]. Recently, it has been shown that the expression of
the miR-17~92 cluster is regulated by TCR signaling
and, in this way, indirectly by miR-181a. The expression
of miR-17~92 can inhibit CD69 expression, which is also
activated by TCR signaling. With this feed forward loop,
cell-to-cell variation in the thymocytes is regulated. This
further marks the importance of miRNAs during normal
T cell development [154] (Fig. 2).
LncRNAs in T cell development
As lncRNAs are known to be expressed tissue specific-
ally, it should be no surprise that also lncRNAs are in-
volved in this specific developmental process. However,
not much is known about lncRNAs involved in human
thymopoiesis. Several studies profiled either sorted thy-
mocytes from mice or differentiation stages of mature T
cells [155, 156], thereby already revealing fluctuations in
lncRNA expression during T cell development.
The T-ALL oncogene NOTCH1 is also necessary for T
cell lineage commitment in the first stages of T cell de-
velopment. NOTCH1 signaling is high in the CD34+
thymocytes but drops significantly during the β-selection
process when the cells differentiate towards CD4+CD8+
double positive thymocytes. In addition to the role of
NOTCH1 in lncRNA expression in T-ALL (see above),
Durinck et al. also examined lncRNAs in T cell develop-
ment [102]. Human thymic CD34+ progenitor T cells
were plated on an OP9 stromal cell layer that expresses
the NOTCH ligand DLL-1 (delta-like ligand 1), leading
to activation of NOTCH1 signaling. RNA - sequencing
was performed after 48 hours of co-culture and showed
a clear shift in lncRNA expression. Furthermore, ex vivo
purified human thymocyte subsets (CD34+CD1−CD4+,
CD34+CD1+CD4+, CD4+CD8+CD3−, and CD4+CD8
+CD3+) were profiled on an expression array that
detected also lncRNAs. The NOTCH-regulated lncRNAs
selected from the co-culture experiment clearly followed
the expression pattern of DTX1, a protein-coding
NOTCH1 target gene that is expressed in CD34+ thymo-
cytes but not in CD4+CD8+ double positive T cells. With
this study, the importance of NOTCH1 in the regulation
of lncRNA expression during T cell development was
clearly shown. Expression profiling of these T cell sub-
sets also revealed several other lncRNAs with dynamic
expression patterns during human T cell development,
suggesting that these also have specific roles during the
T cell maturation process [103].
To elucidate the molecular mechanisms that control
early hematopoietic lineage choices in human, Casero et
al. performed RNA - sequencing on several stages of B
and T cell development [157]. Also here, stage-specific
patterns of lncRNA expression were identified during
the different stages of T cell development. Remarkably,
cell type-specific lncRNAs, and not high expressed
lncRNAs, were characterized by high densities of
H3K4me1 and H3K4me3 histone modifications (marks
for respectively active enhancers and promoters). An-
other interesting difference between lncRNAs and
protein-coding genes was detected if the samples were
clustered based on differentially expressed genes. For
protein-coding genes, the CD34+ thymic progenitor cells
segregated with the CD34+ populations in the bone mar-
row and not with more mature (CD34−) thymic progeni-
tor cells. However, lncRNAs clearly made the distinction
between thymic cells and bone marrow-derived cells.
With these data, the authors could show that the cell
type-specific nature of lncRNA expression could be used
to define developmental relationships.
Despite the low amount of studies describing the role
of miRNAs and lncRNAs in early T cell development,
they already suggest that noncoding RNAs complement
protein-coding genes in their ability to guide early T cell
progenitors through the different maturation stages.
Conclusions
The role for miRNAs and long noncoding RNAs has
been described in several cancer entities and in develop-
mental processes. However, it remains a challenge to de-
fine the functional activities of these noncoding RNAs,
especially for long noncoding RNAs since their potential
mechanism of action can be very broad. Nevertheless,
the oncogenic roles for several miRNAs (ex. the miR-
17~92 cluster [23]) and lncRNAs (ex. MALAT1,
HOTAIR… [52, 53]) have been described in detail for
several cancer entities.
In T-ALL, the role for miRNAs is already explored
in depth. One landmark publication by the Wendel
team could link several miRNAs to protein-coding
genes with a known tumor suppressive role in T-ALL,
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also showing the cooperative effect of several miRNAs
on the same mRNA [121]. This paved the way for
several other studies that could expand this miRNA-
mRNA network. Also in T cell development, there
seems to be a role for miRNAs; however, more in-
depth studies should be performed to profile the miR-
NAs that have key roles during these developmental
steps.
The role for lncRNAs in T-ALL and T cell develop-
ment is less established in comparison to miRNAs.
Nevertheless, the discovery of LUNAR1, a NOTCH1-
activated lncRNA that regulates the expression of
IGF1R in T-ALL [118], proves that there are lncRNAs
involved in the oncogenic development of T-ALL. Fur-
thermore, several studies identified lncRNAs with a
specific expression pattern in T-ALL and T cell devel-
opment, but the functional mechanisms of these
lncRNAs have not been discovered. This is partly due
to the lack of species conservation of lncRNAs, which
makes it difficult to study them in mouse models, but
also because a detailed study describing an in-depth
and full transcriptome of all discrete stages of human T
cell development is still missing. Another obstacle is
the broad range of possible functional mechanisms that
lncRNAs could have, which is not the case for miRNAs,
and the lack of robust genetic tools in human primary
hematopoietic precursors cells to functionally study the
role of individual lncRNAs.
As more and more functions for miRNAs and
lncRNAs are discovered, several possible pharmaco-
logical inhibitory mechanisms, for example the usage
of antisense oligonucleotides, are being tested to
target these noncoding RNAs [158, 159]. The inter-
esting feature of noncoding RNAs is that their
expression is more tissue specific than most protein-
coding oncogenes. Drugs targeting these tissue spe-
cific RNAs could then result in less off-target effects
of the therapy. Because of this, noncoding RNA re-
search with a focus on these ectopic expressed non-
coding RNAs should be further established, taken
into account that there should also be a possibility
to identify patients in clinic that could benefit from
these specific treatments.
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